Janux Therapeutics Inc (NASDAQ:JANX) shares, rose in value on Friday, March 28, with the stock price down by -2.28% to the previous day’s close as strong demand from buyers drove the stock to $29.10.
Actively observing the price movement in the last trading, the stock closed the session at $29.78, falling within a range of $28.91 and $30.07. The value of beta (5-year monthly) was 3.223. Referring to stock’s 52-week performance, its high was $71.71, and the low was $28.92. On the whole, JANX has fluctuated by -9.09% over the past month.
With the market capitalization of Janux Therapeutics Inc currently standing at about $1.72 billion, investors are eagerly awaiting this quarter’s results, scheduled for on 2025-Feb-26.
Wall Street analysts also predicted that the company’s y-o-y revenues would reach 590.91k.
Technical indicators serve as essential tools for traders, offering insights into market sentiment and potential price movements. We see that JANX’s technical picture suggests that short-term indicators denote the stock is a 100% Sell on average. However, medium-term indicators have put the stock in the category of 100% Sell while long-term indicators on average have been pointing out that it is a 50% Sell.
The stock’s technical analysis shows that the price of JANX currently trading nearly -5.11% and -18.46% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 35.84, while the 7-day volatility ratio is showing 5.21% which for the 30-day chart, stands at 5.28%. Furthermore, Janux Therapeutics Inc (JANX)’s beta value is 3.24, and its average true range (ATR) is 1.76.
A comparison of Janux Therapeutics Inc (JANX) with its peers suggests the former has fared considerably weaker in the market. JANX showed an intraday change of -2.28% in last session, and over the past year, it shrunk by -25.08%%.
Data on historical trading for Janux Therapeutics Inc (NASDAQ:JANX) indicates that the trading volumes over the past 10 days have averaged 0.69 and over the past 3 months, they’ve averaged 960.94K. According to company’s latest data on outstanding shares, there are 59.06 million shares outstanding.
Nearly 16.13% of Janux Therapeutics Inc’s shares belong to company insiders and institutional investors own 107.90% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 10.5 million shares as on 2025-03-14, resulting in a short ratio of 11.47. According to the data, the short interest in Janux Therapeutics Inc (JANX) stood at 3150.00 of shares outstanding as of 2025-03-14; the number of short shares registered in 2025-02-14 reached 9.09 million. The stock has fallen by -45.65% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the JANX stock heading into the next quarter.
